Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Trending on Bing
Music legend Jones dies
Diagnosed with cancer
How to vote
Holds rally in Michigan
Holds rally in Pennsylvania
Euthanized in New York
South Carolina fined $250K
Ejected for throwing punch
Israel ends agreement
Raiders fire Luke Getsy
WA mall shooting arrest
Taurid meteor showers
Approves Emrosi for rosacea
IA voter challenges allowed
China crew returns to Earth
Iranian-American detained
DC boosts security efforts
Airstrikes hit Gaza
Win New York City Marathon
NC sees turnout record
Golden Glove winners
Hand-in ballots suit rejected
Penalized by NASCAR
Portis' home burglarized
OPEC extends output cuts
Massachusetts brush fires
Tops box office again
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly Stock Tumbles
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread shortages in the U.
Eli Lilly Stock Tumbles After Disappointing Obesity Drug Sales
Eli Lilly shares slid after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inventory decreases by wholesale distributors hurt sales of its diabetes drug Mounjaro and anti-obesity medicine Zepbound.
Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling
Eli Lilly's high profile weight-loss and diabetes drugs fell short of Wall Street sales estimates on Wednesday as supplies sat in warehouses, a 180-degree turn for the company after long struggling to meet outsized demand.
12d
on MSN
Lilly's weight loss drug shortage deemed over, but hurdles remain
For many patients on tirzepatide, a transformative medication used for weight loss and diabetes, the end of the drug's ...
4d
Ozempic, Wegovy move closer to no longer being in shortage, FDA says
Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...
6d
on MSN
What You Need To Know Ahead of Eli Lilly's Earnings Wednesday
Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...
4d
on MSN
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
The American Journal of Managed Care
3d
5 Essential Drugs Currently Facing Shortages
US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...
7h
Novo's new obesity drug, Wegovy in race to becoming top selling franchise
The Danish drugmaker’s arch-rival
Eli
Lilly
& Co. has introduced another shot ... the diabetes shot that’s often taken ...
4d
on MSN
Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...
4d
on MSN
Hims & Hers stock falls 14% after FDA changes semaglutide supply status (update)
Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...
12d
Shady drugmaker used code words to sell knockoff weight-loss drug: Lawsuit
Amid ongoing legal battles over coveted GLP-1 therapies, a drug vendor in Washington state is accused of running an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback